Clinical Trial Update: Feasibility Study of IV Recombinant Tissue Plasminogen Activator (rtPA) vs. Primary Endovascular Therapy for Acute Ischemic Stroke [Phase 2]

View source ↗

Summary

A Phase 2 feasibility trial comparing intravenous alteplase (rtPA) to primary endovascular therapy for acute ischemic stroke was terminated; results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Alteplase (rtPA) (recombinant tissue plasminogen activator)

Snippet

Sponsor: Mayo Clinic | Conditions: Stroke, Ischemic Stroke | Phase 2 | Status: TERMINATED | Results posted: 2016-10-05